News Tagged ‘kidney failure’

Pre-emption could give Bayer an escape from Trasylol case

Zero accountability for drug companies?

Bloomberg recently ran an article about pharmaceutical companies enjoying their “get out of jail free cards” — revisions to regulations that favor the rights of pharmaceutical companies over consumers who use their drugs. The revised regulations, written just after George W. Bush’s second inauguration in 2005, allow federal law to trump state law, thereby clearing the path for drug manufacturers to develop, test, market, and essentially do business with impunity from the law.

Read the rest of this entry »

Zero accountability for drug companies?

Bloomberg recently ran an interesting and comprehensive article about pharmaceutical companies enjoying their “get out of jail free cards” — revisions to regulations that favor the rights of pharmaceutical companies over consumers who use their drugs. The revised regulations, written just after George W. Bush’s inauguration in 2005, allow federal law to trump (or pre-empt) state law, thereby clearing the path for drug manufacturers to develop, test, market, and essentially do business with impunity from the law.

Read the rest of this entry »

Two suits filed against Bayer in Illinois

Two Illinois residents have filed suit against Bayer, claiming that Trasylol injections led to acute renal failure and other problems in one case and death in the other.

Read the rest of this entry »

Trasylol Pulled From Worldwide Market

Bayer AG suspended worldwide sales of Trasylol, a clotting drug using during heart surgery to prevent bleeding, on Monday following a request from the U.S. Food and Drug Administration to remove the drug from the American market for safety reasons.

Read the rest of this entry »

Trasylol: just one of Bayer’s woes

An article in this week’s Business Week reveals a dualistic Bayer. On one hand, the pharmaceutical giant is “flush with success,” with projected sales just shy of $50 billion and increased dividends for shareholders. On the other hand, Bayer has been racked by a sequence of bad luck that threatens to sully its future fiscal health and innovation. What are the elements at work behind this dichotomy?

Read the rest of this entry »